UniTS
University of Trieste
SCHOOL OF MOLECULAR
BIOMEDICINE
PhD program in Molecular Biomedicine
Home
Board of teachers
 
 
 

 

Prof. Claudio Tiribelli

Centro Studi Fegato (CSF)
AREA Science Park - Basovizza Campus SS14 Km 163,5
34012 Trieste - Italy

e-mail: ctliver@csf.units.it

Phone +39 040 375 7840
Fax +39 040 375 7832

Centro Clinico Studi Fegato (CCSF)
Ospedale di Cattinara 34149 Trieste


phone +39 040 399 4044
fax +39 040 399 4226


Profilo biografico

• Nato a Mestre-Venezia il 6 ottobre 1946
• Laureato in Medicina e Chirurgia, Università di Padova, luglio 1971, summa cum laude
• Specializzato in Gastroenterologia, Università di Trieste, luglio 1975, summa cum laude
• Sposato con Rita Russo, un figlio Mario

Posizioni Accademiche
• 1972-1974: Borsista CNR presso Università di Trieste
• 1974-1988: Ricercatore presso la Facoltà di Medicina, Istituto Patologia Medica, Università di Trieste
• 1989-2008: Professore Ordinario di Biochimica Clinica, Dipartimento Biochimica, Biofisica e Chimica Macromolecole, Università di Trieste
• 2008-ogg: Professore Ordinario Gastroenterologia, Università di Trieste
• 1990-2000: Visiting Professor, Department of Chemistry/Life Sciences, Polytechnic University, Brooklyn, NY, USA
• 1995-oggi: Visiting Professor, Department of Clinical Pharmacology, University of Toronto, Toronto, Ontario, Canada e membro della Faculty

Periodi Sabbatici
• Visting Research Scientist, Department of Pharamacology, State University, Groningen, The Netherlands (febbraio-giungo 1982)
• Visiting Professor and Scientist, Polytechnic University, Brooklyn, NY, USA (1989)
• Visiting Professor, Department of Clinical Pharmacology, University of Toronto, Toronto, Ontario, Canada (1995).

Posizioni Scientifiche
• Membro del Scientific Committee, European Association for the Study of the Liver (EASL)
• Secretary, European Association for the Study of the Liver (EASL)
• Corresponding Secretary, European Association for the Study of the Liver (EASL)
• Membro rappresentante EASL nel consiglio direttivo dell'International Association for the Study of the Liver (IASL)
• Project Leader, studio multicentrico del International Association for the Study of the Liver (IASL) sul carcinoma primitivo del fegato
• 1989, 1992, 1995 e2004: Co-Director, International Bilirubin Workshop
• Presidente del Comitato Scientifico, Fondo Studio Fegato
• 1993-oggi: Presidente Fondo Studio Fegato
• 1992-1998: Secretary of the Educational Committee of the European Association for the Study of the Liver (EASL)
• 2003-oggi: Direttore Centro Studi Fegato

Memberships
• European Association for the Study of the Liver. American Association for the Study Liver Diseases • International Association for the Study of the Liver • Italian Association of Gastroenterology • Associazione Italiana Studio Fegato • Italian Society of Biochemistry • Italian Society Clinical Chemistry & Biochemistry • Asian Pacific Association Study Liver • New York Academy of Science • Sigma XI • Who is Who America / World / Eminences in Medicine/Eminences in Science

 

Interessi di ricerca

1. Meccanismi molecolari del danno neurologico da bilirubina
2. Generazione topo KO Gunn
3. Geni coinvolti nel cancro del fegato
4. Modelli animali di cancro del fegato
5. Modelli in vitro di steatosi
6. Metabolomica delle malattie di fegato (steratosi e cancro)
7. Metabolomica delle malattie di fegato (steratosi e cancro)

 

Pubblicazioni selezionate

Gennuso F, Fernetti C, Tirolo C, Testa N, L’Episcopo F, Caniglia S, Morale MC, Ostrow JD, Pascolo L, Tiribelli C, Marchetti B. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). PNAS 2004, 101:2470-2475.

Calligaris S, Cekic D, Roca-Burgos L. Gerin F, Mazzone G, Ostrow JD, and Tiribelli C. Multidrug Resistance Associated Protein 1 protects against bilirubin-induced cytotoxicity. FEBS Letters, 2006, 580:1355-1359.

Falcao AS, Bellarosa B, Fernandes A, Brito MA, Silva RFM, Tiribelli C, Brites D. Role of multidrug resistance-associated protein 1 (Mrp1) expression in the in vitro susceptibility of rat nerve cell to unconjugated bilirubin. Neuroscience 2007, 144:878-888

Cesaratto L, Calligaris S, Vascotto C, Deganuto M, Bellarosa C, Quadrifoglio F, Ostrow JD Tiribelli C, and Tell G. Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J Mol Med, 2007, 85:1099-1112

Corich L, Aranda A, Carcassa L, Bellarosa C, Ostrow JD and Tiribelli C. The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochem J, 2009, 417:305-321

Ostrow JD and Tiribelli C. New Concepts in Bilirubin Neurotoxicity and the Need for Studies at Clinically Relevant Bilirubin Concentrations (Editorial). J.Hepatol., 2001;34:467-470

Ostrow JD and Tiribelli C. Bilirubin, a curse and a boon. GUT, 2003, 52:1668-1670.

Tiribelli C and Ostrow JD.The molecular basis of bilirubin encephalopathy and toxicity: Report of an EASL Single Topic Conference, Trieste, Italy, 1-2 October, 2004. (Review Article) J Hepatol. 2005 43:156-66.

Ostrow JD, Pascolo L, Brites D and Tiribelli C. Molecular Basis of Bilirubin-Induced Neurotoxicity (Review Article). Trends in Mol Med, 2004,10:65-70.

 

 
back to the home page